Sign In
Buy GTHX
$7.15
+0 (+0%)
At Close: Dec 16, 2024
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09:00pm, Monday, 03'rd Oct 2022 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., Oct. 03, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exerc
G1 Therapeutics: Building A Franchise
11:46am, Thursday, 29'th Sep 2022
Today, we put G1 Therapeutics, Inc. in the spotlight. The company's main asset is COSELA, a small-molecule, short-acting, inhibitor of cyclin-dependent kinases 4 and 6.
G1 Therapeutics to Participate Virtually in the H.C. Wainwright 24th Annual Global Investment Conference
12:00pm, Wednesday, 07'th Sep 2022 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., Sept. 07, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that Jack Bailey, G1’s Chief Executive O
G1 Therapeutics to Participate Virtually in the H.C. Wainwright 24th Annual Global Investment Conference
08:00am, Wednesday, 07'th Sep 2022
RESEARCH TRIANGLE PARK, N.C., Sept. 07, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that Jack Bailey, G1's Chief Executive Offic
G1 Therapeutics to Host Virtual R&D Day on September 15, 2022
11:00am, Tuesday, 06'th Sep 2022 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., Sept. 06, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will host a virtual R&D D
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09:22pm, Thursday, 01'st Sep 2022 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., Sept. 01, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exer
G1 Therapeutics (GTHX)'s Technical Outlook is Bright After Key Golden Cross
01:55pm, Friday, 26'th Aug 2022 Zacks Investment Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Can G1 Therapeutics (GTHX) Climb 150% to Reach the Level Wall Street Analysts Expect?
01:55pm, Monday, 08'th Aug 2022 Zacks Investment Research
The mean of analysts' price targets for G1 Therapeutics (GTHX) points to a 149.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among
Why Quoin Pharmaceuticals Plunged Over 62%; Here Are 120 Biggest Movers From Friday
07:05am, Monday, 08'th Aug 2022 Benzinga
Gainers
Cooper-Standard Holdings Inc. (NYSE: CPS) jumped 69.6% to close at $8.53 on Friday following better-than-expected Q2 results.
Intelligent Living Application Group Inc. (NASDAQ: ILAG) surged 6
G1 Therapeutics, Inc. (GTHX) Q2 2022 Earnings Call Transcript
08:30am, Thursday, 04'th Aug 2022 The Motley Fool
GTHX earnings call for the period ending June 30, 2022.
G1 Therapeutics, Inc. (GTHX) CEO Jack Bailey on Q1 2022 Results - Earnings Call Transcript
02:32pm, Wednesday, 03'rd Aug 2022
Symbotic Inc. (SYM) Q3 2022 Earnings Conference Call August 1, 2022 5:00 PM ET Company Participants Will Roberts - Head-Corporate Communications Jack Bailey - CEO Jen Moses - CFO Andrew Perry - Chief
G1 Therapeutics (GTHX) Reports Q2 Loss, Tops Revenue Estimates
11:45am, Wednesday, 03'rd Aug 2022 Zacks Investment Research
G1 Therapeutics (GTHX) delivered earnings and revenue surprises of 11.54% and 17.43%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
G1 Therapeutics Provides Second Quarter 2022 Financial Results and Operational Highlights
10:30am, Wednesday, 03'rd Aug 2022 GlobeNewswire Inc.
- Achieved $8.7 Million in Net Revenue from Sales of COSELA® (trilaciclib) in the Second Quarter of 2022 and $10.6 Million in Total Revenue -
G1 Therapeutics (GTHX) Reports Q2 Loss, Tops Revenue Estimates
09:02am, Wednesday, 03'rd Aug 2022
G1 Therapeutics (GTHX) delivered earnings and revenue surprises of 11.54% and 17.43%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09:15pm, Monday, 01'st Aug 2022 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., Aug. 01, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exerc
